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Serum levels of macrophage migration inhibitory factor in children and 
adolescents with autistic disorders  
 
INTRODUCTION 
In the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV), autism is 
classified as one of the five pervasive 
developmental disorders (PDDs) and is 
characterized by impairments in the three domains 
of social interaction, communication, and repetitive 
behaviors.1-2 
Autism or autistic disorder (AD) is thought to 
involve a complex interaction between multiple and 
variable susceptibility genes,3 epigenetic effects,4 
and environmental factors.5 Many believe that 
autism results when a genetically susceptible child 
is exposed to an environmental trigger. Research 
into the pathophysiology of autism suggests 
multiple potential mechanisms, further supporting 
the likelihood of different groups of autism.6  
There is emerging evidence and growing 
concern that a dysregulated or abnormal immune 
response may be involved in some forms of AD. In 
general, the links between the immune and 
neurological systems are becoming increasingly 
well known. Aberrant immune activity during 
critical periods of brain and neuronal development 
could potentially play a role in neural dysfunction, 
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typical of autism. Several lines of research have 
shown abnormalities in the nature, extent, and 
regulation of the immune response in autism, 
including a skewed generation of antibodies, 
cytokines, and immune cells.7-12 
For the survival of all living creatures, an 
appropriate and balanced immune response to 
invading micro-organisms is essential. Macrophage 
migration inhibitory factor (MIF) is a distinctive 
cytokine that is secreted by both the anterior 
pituitary and immune cells in response to surgical 
stress, injury, and sepsis.13-14 Accumulating data 
clearly demonstrate the role of MIF in modulating 
the innate immunity.15-16 MIF increases 
lipopolysaccahride (LPS) responsiveness by 
increasing toll-like receptor 4 (TLR4) levels, 
through a pathway that involves the transcription 
factor PU.1.15 An additional mechanism for MIF's 
role in sustaining monocyte/ macrophage activation 
and proinflammatory cytokine production in innate 
immune responses has been provided by Mitchell et 
al.,16 who observed enhanced apoptosis of activated 
macrophages in  MIF knock-out (MIF -/-) mice. In 
a clinical setting, it is likely that MIF regulates both 
early host responsiveness (via TLR4) and late phase 
toxicity to LPS (via enhanced macrophage 
activation and proinflammatory cytokine 
production).14 
Furthermore, there is some evidence 
demonstrating a role of MIF in regulating the 
adaptive arm of the immune response, as well. MIF 
stimulates Th1 immune activity and induces 
proinflammatory cytokines and amplification of 
macrophage function. Within the context of 
inflammatory responses, the Th1 pathway controls 
macrophage activity, which is the main source of 
proinflammatory cytokines. These proinflammatory 
cytokines are highly pleiotropic and stimulate 
neutrophil and macrophage function and, in 
addition, induce production of acute phase 
proteins.17 The principle Th1 cytokine, namely IFN-
γ, is a potent stimulator of monocyte 
chemoattractant protein-1, which further stimulates 
macrophage function.17-18, 13  
Given the role it plays in both innate and 
adaptive immunity, and its widespread secretion, 
we were stimulated to investigate serum levels of 
MIF in a group of children and adolescents with 
autism in relation to disease severity, important 
disease manifestations and associated findings such 






Study population   
This case control study was conduced on 21 
children and adolescents with autistic disorder (AD) 
recruited from Pediatric Neurology and Pediatric 
Outpatient clinics of Ain Shams University in the 
period from the beginning of December 2007 to the 
end of March 2009. They were 16 males and 5 
females. Their ages ranged between 3 and 14 years 
(mean± SD: 6.9± 2.9years). 
 
Inclusion criteria:  
Patients included in the study were fulfilling the 
criteria for the diagnosis of autism according to the 
DSM IV diagnostic criteria for research.1 Patients 
with classic-onset and those with regressive autism 
were both included. 
Exclusion criteria:  
• Patients with associated neurological or metabolic 
disorders (e.g.  cerebral palsy, tuberous sclerosis, 
..etc), other than mental retardation. 
• Patients with other chronic illness, e.g. 
automimmune diseases. 
• Patients with intercurrent infection were excluded 
from the study till resolution of infection. At the 
time of venipuncture, all the study subjects were 
afebrile, were not on antibiotics, and had no 
evidence of acute microbial illnesses by physical 
examination. 
 
Autistic patients were studied in comparison to 
24 age- and sex- matched clinically healthy children 
and adolescents serving as healthy controls. Their 
mean age was 6.08± 3.01 years. They were the 
apparently healthy sibs of the children attending the 
Outpatients Pediatric Clinic, Faculty of Medicine, 
Ain Shams University for minor illness.  None of 
the included control subjects had history or clinical 
findings suggesting a neuropsychiatric disorder, or 
other chronic disease. The study was approved by 
the local ethical committer. Consents were obtained 
from the legal guardians of the included subjects 
after explaining the nature of the study to them. 
 
Clinical evaluation of patients with autism. 
This was based on medical history taking from 
caregivers, clinical examination, and neuro-
psychiatric assessment. In addition, disease severity 
was assessed using Childhood Autism Rating Scale 
(CARS),19 which rates the child on a scale from 1 to 
4 in each of 15 areas (relating to people; emotional 
response; imitation; body use; object use; listening 
response; fear or nervousness; verbal 
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communication; nonverbal communication; activity 
level; level and consistency of intellectual response; 
adaptation to change; visual response; taste, smell, 
and touch response and general impressions). 
According to the scale, children who have scored 
30-36 have mild to moderate autism, whereas those 
with scores above 36 have a severe degree of 
autism. 
Patients were evaluated for history suggestive 
of frequent infections (more than 6/year 
documented by a physician)11. Family history of 
autoimmune diseases was ascertained in controls 
and autistic subjects in an identical manner. Parents 
were asked if a first- or second-degree relative had 
received a diagnosis of specified autoimmune 
disorder. A list of autoimmune diseases with 
descriptions was provided.  
  
Assessment of cognitive abilities of autistic 
children.  
This was done by using Stanford-Binet test20 to 
calculate the intelligence quotient. Subnormal 
intellectual function is diagnosed when intelligence 
quotient is below 70. 
 
Performance of electroencephalogram for autistic 
children.  
Sleep-deprived interictal electroencephalograms 
were performed for the included patients, whenever 
possible with photic and hyperventilation 
provocation. 
 
Assessment of serum MIF levels for the patients 
and the control group  
This assay uses the quantitative sandwich-type 
enzyme immunoassay technique (R&D Systems, 
Inc. Minneapolis, MN 55413, USA). The samples 
were run in a blinded manner, in parallel on the 
same run with the same internal standards. A 
monoclonal antibody specific for MIF has been 
precoated onto a microplate. Standards and samples 
were plotted into the wells and any MIF present is 
bound by the immobilized antibody. After washing 
away any unbound substance, an enzyme- linked 
polyclonal antibody specific for MIF was added to 
the wells. Following wash to remove any unbound 
antibody-enzyme reagent, a substrate solution is 
added to the wells and color develops in proportion 
to the amount of MIF in the initial step. The color 
developed was stopped by adding an acidic stop 
solution. The intensity of the color produced in the 
procedure was measured in a microtiter plate reader 




The results were analyzed by commercially 
available software package (Statview, Abacus 
concepts, Inc., Berkley, California). The data were 
nonparametric, thus, they were presented as median 
and interquartile range [between 25th and 75th 
percentiles]. Mann-Whitney test was used for 
comparison between these data. The χ2 test was 
used for comparison between qualitative variables 
of the studied groups. Spearman’s rank correlation 
coefficient “r” was used to determine the 
relationship between different variables. For all 





Clinical data of the patients group 
Clinical data of the included children and 
adolescents are summarized in Table (1). According 
to the childhood autism rating scale (CARS), 11 
(52.4%) patients were classified as having mild to 
moderate autism and ten had severe autism. Autistic 
regression was identified in four (19%) of the 
included subjects, who lost previously acquired 
language and behavioral skills after 18-24 months 
of age. 
Of the studied autistic children, 12 (57.1%) had 
subnormal intellectual function (intelligence 
quotient below 70); ten of them had mild mental 
retardation (intelligence quotient between 50 and 
69). Seizures were reported in only four of the 
included autistic children (19%), all of them had 
severe autistic disorder. Clinically, the seizures 
pattern was focal in two patients, focal with 
secondary generalization in one and generalized-
onset seizures in the fourth patient. Abnormal 
epileptiform encephalogram was detected in seven 
(33.3%) of the studied group (3 had clinical 
seizures). Most of the abnormal findings were in the 
form of focal epileptiform activity mainly in the left 
temporal or centrotemporal regions (four patients) 
and occasionally showing shifting laterality 
between both sides (three patients). Two of the 
patients with abnormal encephalogram had autistic 
regression. 
History suggestive of recurrent infection was 
identified in four patients with mild to moderate 
autism and four with severe disease. Paternal 
consanguinity was comparable in both the patients 
(14.3%) and the control group (16.7%) (χ2 = 0.048, 
P>0.05) and subjects from both groups did not 
report any family history of psychiatric disorders. 
Family history of autoimmune disorders was 
reported in two patients (9.5%) (Hashimoto’s 
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thyroiditis in one patient with a mild to moderate 
disease and Psoriasis in another with severe AD) 
and only one of the control group (4.2%) (Insulin- 
dependent diabetes mellitus). The difference was 
not of a statistical significance (χ2 = 0.52, P> 0.05). 
Patients with severe autistic disorder did not show 
significant difference in the family history of 
autoimmune disorders when compared to those 
with milder phenotype (χ2 = 0.156, P> 0.05). 
 
Serum levels of MIF in patients and controls: 
Levels of MIF, though lower in the patients [mean± 
SD: 3.73± 3.9; median (interquartile range) of 2.5 
(2.65) ng/ml] were not significantly different from 
the levels of the control group [mean± SD: 4.1± 
3.8;  2.5(3.2) ng/ml] (z=0.79, P> 0.05). Levels of 
the MIF were significantly lower in patients with 
severe autistic disorder [median (interquartile 
range) of 1.85 (1.73) ng/ml] compared to those with 
mild to moderate disease [4.0 (4.8) ng/ml] 
(z=2.197, P=0.029) (Fig 1). Correlation of the MIF 
levels to the different behavioral parameters 
assessed by the CARS, revealed a negative 
correlation with the severity of the nonverbal 
communication parameter derangement (r= -0.49, 
P=0.042) (Fig 2).  
Patients with history of recurrent infections did 
not show significant difference in MIF levels 
[median (interquartile range) of 2.5(2.73) ng/ml] 
compared to those without such history [2.5 (2.8) 
ng/ml] (P> 0.05)]. There was no significant 
difference in the levels of MIF in patients with 
subnormal mentality [median (interquartile range) 
of 2.35 (2.73) ng/ml] or in patients with abnormal 
electroencephalogram [median (interquartile range) 
of 4.0(12.0) ng/ml] compared to the rest of patients 
[2.8(2.8) and 2.5(3) ng/ml, respectively] (z=0.61 
and 0.79, respectively, P> 0.05). Also, patients with 
autistic regression did not show significant 
difference in MIF levels [median (interquartile 
range) of 3.1(2.18) ng/ml] when compared to those 
with classic- onset autism [3.49(3.05) ng/ml] 































Figure 1. Serum MIF levels in patients with mild to 
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Figure 2: Correlation of serum levels of MIF to the 




There is increasing evidence of immune 
involvement in AD.21 Dysregulation of the immune 
system in particular subtypes of autism is a subject 
of active investigation in humans and animal 
models.10 At present, views of possible immune 
dysfunction in AD range from conclusions that it 
may contribute to manifestations of the disorder in 
some patients22 to hypotheses that 
neuroimmunopathogenic responses play a 
fundamental role in AD.23 Studies suggest that 
innate rather than adaptive neuroimmune responses 
are associated with AD. 24-26 
The results of the present study showed values 
of MIF that were not significantly different in 
patients and control groups. However, it was noted 
that patients with severe disorder showed 
significantly lower levels of the cytokine than those 
with milder disease.   By comparison, in the only 
other study assessing MIF in AD, the authors 
reported a genetic association between functional 
polymorphisms in the promoter of MIF and autism 
spectrum disorder- related behaviors, with elevated 
levels of MIF in the included patients. They 
proposed an underlying autoimmune basis of the 
disorder.27 The difference in our results may be 
explained on the basis of perhaps another form of 
polymorphism that may result in decreased levels of 
MIF in a subset of patients. This may well explain 
the heterogeneity among AD patients. Whether the 
reported increased MIF levels in the previous 
study27 and also in our subgroup of milder disease, 
though insignificant, may reflect an increased 
production of an aberrant nonfunctioning form of 
the cytokine, and thus may be explained also on the 
basis of immune dysfunction rather than 
autoimmune disorder, is beyond the scope of our 
study. The possible role of derangement of innate 
immune system has been previously reported. In a 
study11 evaluating innate immunity in a subset of 
children with AD, the investigators assessed the 
production of proinflammatory and counter-
regulatory cytokines by peripheral blood 
mononuclear cells (PBMCs) in response to agonists 
of Toll-like receptors (TLRs). The authors noted 
that peripheral blood mononuclear cells (PBMCs) 
from AD test group children produced less IL-1β 
with a TLR7/8 agonist.  Other studies reported 
intrinsic defects of innate immunity with abnormal 
production of proinflammatory cytokines from 
cultured PBMCs.25-26  
Our results and those of other studies might 
indicate a role of MIF deficiency in development of 
severe manifestations of the disease. A possible 
explanation may be through the role the innate 
immunity plays as the first line, antigen-
independent immune defense mechanism. This is 
achieved by recognizing microbial by-products or 
those from damaged tissue cells via pattern 
recognition receptors including TLRs.28-29 TLR-
mediated responses lead to the production of 
various soluble mediators that can signal the 
brain.30-33 Such signaling events help the central 
nervous system restore autonomic homeostasis and 
provide inhibitory regulatory signals to prevent 
excessive immune responses.30  In further support 
of this finding is the significant negative correlation 
between the cytokine and the degree of involvement 
of nonverbal communication parameter of CARS 
which is one of the core features of the disorder. 
The lower the MIF, the worse is the behavioral 
parameter. 
It has been previously noted that a number of 
autistic children suffer from recurrent infections 
(typically viral syndromes) accompanied by 
exacerbations of behavioral symptoms 
(hyperactivity, temper tantrums, irritability and self-
stimulatory behaviors). Immune insult via microbial 
infection caused by various pathogens appears to 
counter-act beneficial effects of behavioral, dietary, 
and other intervention measures in these AD 
children.11 The above-described clinical observation 
was supported by an  open-label trial of 
administration of vancomycin, which resulted in 
objective, cognitive improvements in autistic 
children. Furthermore, there was regression of 
patients’ cognitive functions when it was stopped.35 
This further supports the hypothesis that in these 
AD children, antigen non-specific (innate) immune 
responses are altered, leading to dysregulated 
neuro-immune interactions. That our findings did 
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not show difference in MIF levels between patients 
with recurrent infections and those without may be 
explained by the small number of the included 
group and the need for a more objective evaluation 
of “recurrent infection,” possibly through follow up 
studies. 
It was previously noted that about 20 to 30% of 
AD parents, report the occurrence of language 
regression or a developmental plateau associated 
with loss of sociability in their child between 
approximately 12 to 30 months of age, usually with 
no known trigger (autistic regression),36,8,10 a value 
that is close to our results. Other neurological 
abnormalities have been previously described in 
AD; for example, 30% of children with AD develop 
epilepsy by adolescence,37 and an additional group 
reaching 60% in some studies has subclinical 
epilepsy, as measured by epileptiform 
encephalogram, especially during sleep.38-39 Our 
results showed that 19% of AD patients suffer from 
seizures and nearly one third have abnormal 
epileptiform encephalogram. Both autistic 
regression and findings of epileptiform 
encephalogram clearly indicate that there are 
neurological involvements in AD that affect the 
development and differentiation of neurons in the 
brain. Immune dysregulation could result in the 
generation of localized or systemic inflammation 
and/or the release of immunomodulatory molecules 
that could influence, alter, or modify 
neurodevelopment and/or neuronal function, 
especially at critical times of development.10 
Interestingly, the presence of low-grade chronic 
inflammation has been reported in brain tissue of 
individuals with autism.9, 24 Our results failed to 
demonstrate a significant difference in MIF levels 
in patients with mental retardation or those with 
abnormal electroencephalogram. 
In previous studies on families of affected 
children, results indicated a higher prevalence of 
autoimmune disorders like rheumatoid arthritis, 
lupus, and thyroiditis compared with control 
families,40-41 a finding not corroborated in another 
study.42 Similarly our results did not show 
significant difference in the frequency of 
autoimmune diseases in families of autistic patients 
compared to the control group. This is in 
accordance with our results which suggest 
dysfunction in the innate immune system rather 
than autoimmune disorder as the underlying 
pathogenic mechanism. 
In conclusion, our findings demonstrated MIF 
levels that were significantly lower in a subset of 
patients with severe AD compared to those with 
milder form and even showed a negative correlation 
to the nonverbal communicative difficulties those 
patients experience. These results may indicate a 
role of the cytokine in the development of severe 
manifestations of the disorder. Children with severe 
AD may be less capable of controlling microbial 
infection in the initial stages, leading to ineffective 
signaling to the brain. While the extent to which 
many of the observations discussed herein are 
involved in the pathogenesis of autism is unknown, 
it cannot be discounted that immune dysfunction is 
an epiphenomenon or a consequence of the disease. 
These findings will require additional study in other 
samples of probands with AD to determine their 
replicability. These results also prompt a 
reconsideration of previous observations and 
stimulate the investigation of new hypotheses 
regarding relationships between immune 
dysfunction and AD. Our results may assist in 
better defining AD phenotypes, thereby improving 
the prognosis of behavioral abnormalities and 
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